VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | Assessing the role of daratumumab in ALL

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, talks on the role of daratumumab with or without chemotherapy in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). In a retrospective observational Campus study, the anti-CD38 antibody was found to produce limited responses in patients. Additional research will be conducted in patients with T-cell ALL (T-ALL) and B-cell ALL (B-ALL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter